₦airaland Forum

Don't ask me for source because this is the source.

Following the launch of the COVID ORGANICS aka CVO drug by the government of Madagascar on the 20th of April 2020, which is alleged to cure the virus by the government of Madagascar.
It is said that the United State government has agreed to fund the county's COVID-19 Herbal cure and it failed to receive approval from WHO.
In an interview with the USA ambassador Michael Pelletier, he stated that the American government will fund Madagascar with $2.5 million.
Further stating that "the exclusive allocation of this sum in popularization on the national territory of the solutions found”.
It was also gather from other local sources that German, Danish and American researchers, have combined their efforts to carry out analysis on the preventive and curative scope of the use of artemisia for the treatment of the virus.

xolocious:
I'm still not comfortable calling it love... Give it time... More time to know her better and discover if the love you foresee is true / real.

Yeah sure thanks.

Akinola100:
No. I notice this kind of things in sections like this

Are you Perfect you always see section like this.

xolocious:
I call this infatuation... Not love. You both are in a hurry to fall in love especially she being a single mother. She desperately needs a companion.
Use your head bro.

No bro she doesn't just need a companion because different guys are coming around not even 10.

Renida:
Love can spin one's head. No one is protected against the intoxication of love. God help your soul. Love Don dey tire people like us.

Thanks you are right.

Akinola100:
why do nairalanders always say that they are not good in writing letters,and so making many errors and mistakes. Are they intentionally doing this?

You always look for error why.? Everybody is not intelligent as you.

Hello Guy's Please Don't Mind Mistake I'm Not Too Good Writing Latter's.

Well I Will Go Straight To Point, I Meet This Beautiful Girl Sometime February Or May Ever Since Then We Are Just Friends Because She And my Cousin, Work In Same Restaurant Ever Since The First Day We Meet, She Always Want To Talk To Me Anytime I Went To Visit My Cousin At Work And We Kinda Flow In Anytime Conversation, I Still Like Her Company.

Until Now In This Lockdown First Week Of Lockdown She Always Call Me To Check On Me Daily, And Do A lot Of Talking Always She Always Ask Me If I Have Eaten This Evening Or Morning Always, How Is Today's Have You Head Anything About The Lockdown etc.

But She's With Someone Before I Think And I Tried Talk About It With Her But She Refuse And She Had One Child With His X.

And Now I Don't Know If I'm Doing Wrong Or Not And Again The Kinds Of Words She Use Is Amazing Its Like If You Had A Plan, Or Focus She Will Be Talking To That Point With So Much Positive Words,

Please I Need Some Advice Guy's Please .

COVID-19 vaccine protects monkeys from new coronavirus, Chinese biotech reports
By Jon Cohen Apr. 23, 2020 , 1:05 PM
Science ’s COVID-19 reporting is supported by the Pulitzer Center.

For the first time, one of the many COVID-19
vaccines in development has protected an animal, rhesus macaques, from infection by the new coronavirus, scientists report. The vaccine, an old-fashioned formulation consisting of a chemically inactivated version of the virus, produced no obvious side effects in the monkeys, and human trials began on 16 April.
Researchers from Sinovac Biotech , a privately held Beijing-based company, gave two different doses of their COVID-19 vaccine to a total of eight rhesus macaque monkeys. Three weeks later, the group introduced SARS-CoV-2, the virus that causes COVID-19, into the monkeys’ lungs through tubes down their tracheas, and none developed a full-blown infection.


The monkeys given the highest dose of vaccine had the best response: Seven days after the animals received the virus, researchers could not detect it in the pharynx or lungs of any of them. Some of the lower dosed animals had a “viral blip” but also appeared to have controlled the infection, the Sinovac team reports in a paper published on 19 April on the preprint server bioRxiv. In contrast, four control animals developed high levels of viral RNA in several body parts and severe pneumonia. The results “give us a lot of confidence” that the vaccine will work in humans, says Meng Weining, Sinovac’s senior director for overseas regulatory affairs.
“I like it,” says Florian Krammer, a virologist at the Icahn School of Medicine at Mount Sinai who has co-authored a status report about the many different COVID-19 vaccines in development.

“This is old school but it might work. What I like most is that many vaccine producers, also in lower–middle-income countries, could make such a vaccine.”
But Douglas Reed of the University of Pittsburgh, who is developing and testing COVID-19 vaccines in monkey studies, says the number of animals was too small to yield statistically significant results. His team also has a manuscript in preparation that raises concerns about the way the Sinovac team grew the stock of novel coronavirus used to challenge the animals: It may have caused changes that make it less reflective of the ones that infect humans.
Another concern is that monkeys do not develop the most severe symptoms that SARS-CoV-2 causes in humans. The Sinovac researchers acknowledge in the paper that “It’s still too early to define the best animal model for studying SARS-CoV-2,” but noted that unvaccinated rhesus macaques given the virus “mimic COVID-19-like symptoms.”

The study also addressed worries that partial protection could be dangerous. Earlier animal experiments with vaccines against the related coronaviruses that cause severe acute respiratory syndrome and Middle East respiratory syndrome had found that low antibody levels could lead to aberrant immune responses when an animal was given the pathogens, enhancing the infection and causing pathology in their lungs. But the Sinovac team did not find any evidence of lung damage in vaccinated animals who produced relatively low levels of antibodies, which “lessens the concern about vaccine enhancement,” Reed says. “More work needs to be done though.”

SARS-CoV-2 seems to accumulate mutations slowly; even so, variants might pose a challenge for a vaccine. In test tube experiments, the Sinovac researchers mixed antibodies taken from monkeys, rats, and mice given their vaccine with strains of the virus isolated from COVID-19 patients in China, Italy, Switzerland, Spain, and the United Kingdom. The antibodies potently “neutralized” all the strains, which are “widely scattered on the phylogenic tree,” the researchers noted.

“This provides strong evidence that the virus is not mutating in a way that would make it resistant to a #COVID19 vaccine,” tweeted immunologist Mark Slifka of Oregon Health & Science University. “Good to know.”
Sinovac is an experienced vaccinemaker—it has marketed inactivated viral vaccines for hand, foot, and mouth disease; hepatitis A and B; and H5N1 influenza or bird flu. But Meng says it could produce, at most, about 100 million doses of the vaccine and might need to partner with other makers if the company’s COVID-19 vaccine proves safe and effective in human trials.
The company recently started phase I clinical trials in Jiangsu province, north of Shanghai, which aim to gauge safety and immune responses in 144 volunteers. An equal number of participants will receive the high and low doses or a placebo. Although placebos are not typically used in phase I studies—which do not assess efficacy—Meng says this can help better evaluate whether the vaccine causes any dangerous side effects. The company hopes to start phase II studies by mid-May that have the same design but enroll more than 1000 people, with results due by the end of June.
If all goes well, Meng says, Sinovac will seek to launch traditional phase III efficacy trials that compare the vaccine with a placebo in thousands of people. The company has also discussed joining international vaccine trials being organized by the World Health Organization (WHO).

Given the low level of transmission now occurring in China, the company is considering still more efficacy trials in other countries being hit harder by the virus. “We can’t put all our eggs in one basket,” Meng says.
To quickly obtain more efficacy data after the phase I and II trials and potentially help people, Meng says Sinovac may ask regulatory agencies in China and other countries for emergency authorization to give the vaccine to those at high risk of becoming infected, such as customs agents and police officers who do not typically wear the protective gear used by health care workers. The Democratic Republic of the Congo in 2018 began to widely use an experimental Ebola vaccine under that status and the evidence suggests it powerfully helped curb that epidemic. (That Ebola vaccine first received regulatory approval in November 2019.)

According to WHO , six other vaccines had entered human trials as of 23 April, and 77 others were in development. The vast majority of these vaccines use the modern tools of genetic engineering—only four rely on the old-fashioned inactivation technology—but Meng says what ultimately matters is whether a vaccine is safe and effective, not how it’s made. “We are not comparing ourselves to anyone,” Meng says. “In this pandemic situation, the most important thing is to make a vaccine, no matter what kind of vaccine it is, that’s safe and effective as soon as possible.”

Hello guy's

Hello guy's due to this Corona virus pandemic will chevron internship program July to December commence this year.

sapientia:
He is concerned cos it has to do with eye.
People have been blinded for less things than this.
I don't think you should rely on Nairaland for this.
Get in touch with an expert you can see and talk face to face

Thanks

kunleweb:
Would it hurt you to live with it? Don't injure yourself that area is delicate. Please. Don't begin what you won't be able to finish o

Thanks Sir I appreciate your advice but I just need advice like what cream to apply which can grow my eyebrow hair that all.

Please I need advice on what medication Cream or substance to apply I had an accident wen I was little, and I had a terrible wound close to my eye's and it line's in my right eyes brow.

What I need now its any powerful medication or Cream that can grow up my eyebrow hair to cover my injury for good please any useful advice will appreciated thanks.

Clinical trials, an essential precursor to regulatory approval, usually take place in three phases. The first, involving a few dozen healthy volunteers, tests the vaccine for safety, monitoring for adverse effects. The second, involving several hundred people, usually in a part of the world affected by the disease, looks at how effective the vaccine is, and the third does the same in several thousand people. But there’s a high level of attrition as experimental vaccines pass through these phases. “Not all horses that leave the starting gate will finish the race,” says Bruce Gellin, who runs the global immunisation programme for the Washington DC-based nonprofit, the
Sabin Vaccine Institute .
There are good reasons for that. Either the candidates are unsafe, or they’re ineffective, or both. Screening out duds is essential, which is why clinical trials can’t be skipped or hurried. Approval can be accelerated if regulators have approved similar products before. The annual flu vaccine, for example, is the product of a well-honed assembly line in which only one or a few modules have to be updated each year. In contrast, Sars-CoV-2 is a novel pathogen in humans, and many of the technologies being used to build vaccines are relatively untested too. No vaccine made from genetic material – RNA or DNA – has been approved to date, for example. So the Covid-19 vaccine candidates have to be treated as brand new vaccines, and as Gellin says: “While there is a push to do things as fast as possible, it’s really important not to take shortcuts.”
An illustration of that is a vaccine that was produced in the 1960s against respiratory syncytial virus, a common virus that causes cold-like symptoms in children. In clinical trials, this vaccine was found to aggravate those symptoms in infants who went on to catch the virus. A similar effect was observed in animals given an early experimental Sars vaccine. It was later modified to eliminate that problem but, now that it has been repurposed for Sars-CoV-2, it will need to be put through especially stringent safety testing to rule out the risk of enhanced disease.
It’s for these reasons that taking a vaccine candidate all the way to regulatory approval typically takes a decade or more, and why President Trump sowed confusion when, at a meeting at the White House on 2 March, he pressed for a vaccine to be ready by the US elections in November – an impossible deadline. “Like most vaccinologists, I don’t think this vaccine will be ready before 18 months,” says Annelies Wilder-Smith, professor of emerging infectious diseases at the London School of Hygiene and Tropical Medicine. That’s already extremely fast, and it assumes there will be no hitches.
In the meantime, there is another potential problem. As soon as a vaccine is approved, it’s going to be needed in vast quantities – and many of the organisations in the Covid-19 vaccine race simply don’t have the necessary production capacity. Vaccine development is already a risky affair, in business terms, because so few candidates get anywhere near the clinic. Production facilities tend to be tailored to specific vaccines, and scaling these up when you don’t yet know if your product will succeed is not commercially feasible. Cepi and similar organisations exist to shoulder some of the risk, keeping companies incentivised to develop much-needed vaccines. Cepi plans to invest in developing a Covid-19 vaccine and boosting manufacturing capacity in parallel, and earlier this month it put out a call for $2bn to allow it to do so.
Once a Covid-19 vaccine has been approved, a further set of challenges will present itself. “Getting a vaccine that’s proven to be safe and effective in humans takes one at best about a third of the way to what’s needed for a global immunisation programme,” says global health expert Jonathan Quick of Duke University in North Carolina, author of The End of Epidemics (2018). “Virus biology and vaccines technology could be the limiting factors, but politics and economics are far more likely to be the barrier to immunisation.”
The problem is making sure the vaccine gets to all those who need it. This is a challenge even within countries, and some have worked out guidelines. In the scenario of a flu pandemic, for example, the UK would prioritise vaccinating healthcare and social care workers, along with those considered at highest medical risk – including children and pregnant women – with the overall goal of keeping sickness and death ra tes as low as possible. But in a pandemic, countries also have to compete with each other for medicines.
Because pandemics tend to hit hardest those countries that have the most fragile and underfunded healthcare systems, there is an inherent imbalance between need and purchasing power when it comes to vaccines. During the 2009 H1N1 flu pandemic, for example, vaccine supplies were snapped up by nations that could afford them, leaving poorer ones short. But you could also imagine a scenario where, say, India – a major supplier of vaccines to the developing world – not unreasonably decides to use its vaccine production to protect its own 1.3 billion-strong population first, before exporting any.
Outside of pandemics, the WHO brings governments, charitable foundations and vaccine-makers together to agree an equitable global distribution strategy, and organisations like Gavi, the vaccine alliance, have come up with innovative funding mechanisms to raise money on the markets for ensuring supply to poorer countries. But each pandemic is different, and no country is bound by any arrangement the WHO proposes – leaving many unknowns. As Seth Berkley, CEO of Gavi, points out: “The question is, what will happen in a situation where you’ve got national emergencies going on?”
This is being debated, but it will be a while before we see how it plays out. The pandemic, says Wilder-Smith, “will probably have peaked and declined before a vaccine is available”. A vaccine could still save many lives, especially if the virus becomes endemic or perennially circulating – like flu – and there are further, possibly seasonal, outbreaks. But until then, our best hope is to contain the disease as far as possible. To repeat the sage advice: wash your hands.
This article was amended on 19 March 2020. An earlier version incorrectly stated that the Sabin Vaccine Institute was collaborating with the Coalition for Epidemic Preparedness Innovations (Cepi) on a Covid-19 vaccine.

Coronavirus vaccine: when will it be ready?
Human trials will begin imminently – but even if they go well and a cure is found, there are many barriers before global immunisation is feasible
Coronavirus – latest updates
See all our coronavirus coverage
Sun 29 Mar 2020 14.57 BST
E ven at their most effective – and draconian – containment strategies have only slowed the spread of the respiratory disease Covid-19. With the World Health Organization finally declaring a pandemic, all eyes have turned to the prospect of a vaccine, because only a vaccine can prevent people from getting sick.
About 35 companies and academic institutions are racing to create such a vaccine, at least four of which already have candidates they have been testing in animals. The first of these – produced by Boston-based biotech firm Moderna – will enter human trials imminently .
This unprecedented speed is thanks in large part to early Chinese efforts to sequence the genetic material of Sars-CoV-2, the virus that causes Covid-19. China shared that sequence in early January, allowing research groups around the world to grow the live virus and study how it invades human cells and makes people sick.
But there is another reason for the head start. Though nobody could have predicted that the next infectious disease to threaten the globe would be caused by a coronavirus – flu is generally considered to pose the greatest pandemic risk – vaccinologists had hedged their bets by working on “prototype” pathogens. “The speed with which we have [produced these candidates] builds very much on the investment in understanding how to develop vaccines for other coronaviruses,” says Richard Hatchett, CEO of the Oslo-based nonprofit the
Coalition for Epidemic Preparedness Innovations (Cepi), which is leading efforts to finance and coordinate Covid-19 vaccine development.
Coronaviruses have caused two other recent epidemics – severe acute respiratory syndrome (Sars) in China in 2002-04, and Middle East respiratory syndrome (Mers), which started in Saudi Arabia in 2012. In both cases, work began on vaccines that were later shelved when the outbreaks were contained. One company, Maryland-based Novavax, has now repurposed those vaccines for Sars-CoV-2, and says it has several candidates ready to enter human trials this spring. Moderna, meanwhile, built on earlier work on the Mers virus conducted at the US National Institute of Allergy and Infectious Diseases in Bethesda, Maryland.
Sars-CoV-2 shares between 80% and 90% of its genetic material with the virus that caused Sars – hence its name. Both consist of a strip of ribonucleic acid (RNA) inside a spherical protein capsule that is covered in spikes. The spikes lock on to receptors on the surface of cells lining the human lung – the same type of receptor in both cases – allowing the virus to break into the cell. Once inside, it hijacks the cell’s reproductive machinery to produce more copies of itself, before breaking out of the cell again and killing it in the process.
All vaccines work according to the same basic principle. They present part or all of the pathogen to the human immune system, usually in the form of an injection and at a low dose, to prompt the system to produce antibodies to the pathogen. Antibodies are a kind of immune memory which, having been elicited once, can be quickly mobilised again if the person is exposed to the virus in its natural form.
Traditionally, immunisation has been achieved using live, weakened forms of the virus, or part or whole of the virus once it has been inactivated by heat or chemicals. These methods have drawbacks. The live form can continue to evolve in the host, for example, potentially recapturing some of its virulence and making the recipient sick, while higher or repeat doses of the inactivated virus are required to achieve the necessary degree of protection. Some of the Covid-19 vaccine projects are using these tried-and-tested approaches, but others are using newer technology. One more recent strategy – the one that Novavax is using, for example – constructs a “recombinant” vaccine. This involves extracting the genetic code for the protein spike on the surface of Sars-CoV-2, which is the part of the virus most likely to provoke an immune reaction in humans, and pasting it into the genome of a bacterium or yeast – forcing these microorganisms to churn out large quantities of the protein. Other approaches, even newer, bypass the protein and build vaccines from the genetic instruction itself. This is the case for Moderna and another Boston company, CureVac, both of which are building Covid-19 vaccines out of messenger RNA.
Cepi’s original portfolio of four funded Covid-19 vaccine projects was heavily skewed towards these more innovative technologies, and last week it announced $4.4m (£3.4m) of partnership funding with Novavax and with a University of Oxford vectored vaccine project. “Our experience with vaccine development is that you can’t anticipate where you’re going to stumble,” says Hatchett, meaning that diversity is key. And the stage where any approach is most likely to stumble is clinical or human trials, which, for some of the candidates, are about to get under way.

Only God can Save us

Thanks everyone for wonderful advice and opinions I really appreciate.

bamidelee:
She's marriageable to you
hope your family would understand

I understand perfectly thanks

Masterpiece676:
You don't have problem, you are the problem. How could you be fúcking your cousin?

Listen I didn't have Sex with my cousin Okay stop crating problem were there ain't any.

Investmentfreak:
Solid point. Sex is not all about dick and pussy

Please with due respect Sir please enlighten me more about Sex,
What is Sex.

Elimon:
Lol...you are making me remember my male cousin roommate in Uyo,he had a female cousin also from his pops side...the girl was beautiful although and use to visit regular... She was always very open in sexuality with my cousin,always making me curious.the day my eyes open was wen I went to night class and I came back to see them on the bed and two used condoms on the floor....like I didn't know what to say...I stared at them all day
Shits happening everyday bro
And I wasn't the only one who notice they were fvcking...our neighbors knew too...tho they told me much later after he left

If two opposite sex come together always the unexpected happen.

I just need distance from her and a good advice from NL that's why I'm here.

Some of you will see this the other way around that I'm having an affair with my cousin No I'm not.

Masterpiece676:
Romance, joystick up, bla bla bla. Are you expecting the op to tell you what later went down? Well, sex is not all about pussy and dick though

Dude listen if I did I won't mention about joy stick up because I knew some will think I'm having sex with her but that's not true.

I only come here to seek advice nothing more and that's true because I don't lie for any reason.

frubben:
your write up just gave me serious headache.

My opinion though. Which am entitled to

I'm sorry Sir I know I mess up during the writing sorry for the headache.

Investmentfreak:
I didn’t say you should sleep with her o, just clarifying that it’s not bad as people paint it.

I understand perfectly okay Sir and beside I don't such intension anymore thanks.

Investmentfreak:
Please can you give a bible reference where it is condemned? Cain married his sister, lot slept with his daughters, absaloms sister was raped by her step brother and Jacob married his relative.
Happy Sunday

That's true well said at this point in my life, I really someone at the same time I need a job too to put food on my table I have my own apartment,

I already set my aim and goal so all my focus is to get a job first before rethinking about relationship.

I can't been broke and have a relationship with someone and this day's some girls patience and understand and on the other hand my cousin want me to have a relationship with someone, because she once said she doesn't like seeing me feel lonely because most times all I need to be alone No disturb and that's we're exactly she comes in.

excanny:
Your cousin sister has nothing but pure family care but you are the one thinking nonsense in your head.

But you should know she's related to you and such incestuous thoughts should never come to ur head ever.

I'm really worried that you can't control yourself around a blood sister. That means you will be misbehaving around your daughters too?

Give urself brain, Oga.

Thanks Sir very much for your wonderful opinion I feel better yesterday after reading your post I now have clear conscience yesterday evening when she came visits.

Even at night I feet good like never before all my thought all through when she came is family caring nothing more,

I mean thank you Sir unlike before my thought is to have Sex and it really get me confuse until I decide to see advice on NL.

Investmentfreak:
Please can you give a bible reference where it is condemned? Cain married his sister, lot slept with his daughters, absaloms sister was raped by her step brother and Jacob married his relative.
Happy Sunday

Thanks for the bible reference but in today christian I don't think anything like that will ever happen again

Iyiataata92:
I'm not the first person that criticised your error ridden post. I'm not proud bro. but make correct posts next time

Honestly I was expecting an advice from you not the some errors I make while typing and yet other people are giving in good advice but you choose for my errors

GraGra247:
Please don't ever listen to this advice of total madness and blindness.

Never sleep with your own cousin!!

Hear me again; never ever sleep with your own cousin!!!

The bad luck it brings, prayer and fasting go even tire you. Native doctor self go tire for your matter.

Don't say you weren't warned. Girls full everywhere.

Thanks a lot

24kmagic:
Just fvck her already

Can you have Sex with Your sister

justnock:
Get a girlfriend or befriend ladies that can keep you company. It will put her off.
Maybe she has a crush on you or just wants to experiment with you. Don't. It is a taboo to smash your blood.

Thanks it seems very much like it